AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Candlesense
AIM Clinical trials

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer
Find similar articles on Candlesense globenewswire